
## Hair: continuously self-regenerating

- ► The full head of hair consists of 110,000 - 150,000 hairs
- ► The average of scalp surface is 600 cm<sup>2</sup> <sup>1,2</sup>
- Each hair is produced by a single hair follicle
- Each hair follicle produces an average of 30 hairs during our life
- Hair grows at 1 cm per month which corresponds to:
  - 0.3 to 0.5 mm per day
  - about 10 cm per year
- ▶ We lose naturally from 50 to 100 hair each day.

The hair structure is divided in 2 sections: the hair follicle and the hair shaft



### Zoom on the hair structure



#### What are Stem Cells

Stem cells are non differentiated cells

They have two key features:

- Self renewal: they can give birth to other stem cells
- Potency: they can give birth to specialized cell types

#### Stem cells are divided in two broad categories:

- Embryonic stem cells, which are totipotent: they can create a complete human being
- Adult stem cells, which are multipotent: they can generate an organ

Stem cells are at the origin of our body self regeneration faculties.



More information on: <a href="http://stemcells.nih.gov">http://stemcells.nih.gov</a>

## Stem cells in regenerative medicine

Stem cells therapy has been a key fundamental research area for more than 30 years.

**Concept:** introduce new adult stem cells into damaged tissues and organs to regenerate them

#### **Targeted diseases:**

- Leukemia (bone marrow)
- Parkinson's and Alzheimer's diseases (neurons)
- Type I diabetes (pancreas)
- Cancers (brain)
- Heart failure (heart)
- Muscles atrophy (muscles)
- Wound healing (skin)
- Baldness (hair) <sup>1</sup>



In 2013, 500 clinical trials based on stem cells therapy have been initiated <sup>2</sup>


<sup>&</sup>lt;sup>1</sup> Yang et al. Nature Communications, 2014

<sup>&</sup>lt;sup>2</sup> www.clinicaltrials.gov

### Stem cells in skin

#### Stem cells are mainly found in

- The hypodermis
- The basal layer
- The sebaceous gland
- The bulge (ORSc stem cells)




Diaz-Flores, 2006, Histol Histopathol.

## Bulge stem cells (ORSc)

Bulge stem cells are mother cells, generating:

- the epidermis cells,
- the hair follicle matrix,
- the sebaceous gland stem cells.



Diaz-Flores, 2006, Histol Histopathol.


### Bulge stem cells (ORSc)

Bulge stem cells are expressing the keratin 15 marker.

They have a key role in the regeneration of the hair follicle.

Bulge stem cells are initiating the hair cycle.

## THE HAIR CYCLE IS DIVIDED IN 3 STEPS



Fuchs et al., 2008, Journal of Cell Biology

## Step 1: ANAGEN - Growing phase

Anagen phase is the active phase of the hair (80% to 90% of all hair).

Keratinocytes in the matrix at the root of the hair are dividing rapidly.

During this phase the hair grow about 1 cm every month.

Scalp hair stays in this active phase of growth for 2-6 years.



Randall 2009. The biology of hair growth, Gurpreet S. Ahluwalia (ed.), Cosmetic Applications of Laser and Light-Based Systems, 3-35, William Andrew Inc.

## Step 2: CATAGEN - Transition phase

Catagen phase is a transitional stage and 2% of all hairs are in this phase.

This phase lasts for about 2-3 weeks.

During this phase, hair growth stops.



## Step 3: TELOGEN - Falling phase

Telogen phase is the resting phase and accounts for 10-15% of all hairs.

This phase lasts for about 3 months.

During this phase the hair follicle is at rest and the club hair is completely formed.


During a period of intensive hair loss, up to 30% of the hairs can be in the telogen phase.



### Transition to a new cycle

Early Anagen phase is the activation of a new hair cycle growth.


A new hair is formed and pushes the club hair up the follicle and eventually out.



## Early anagen: chronology of the communication

Cells from the dermal papilla activate bulge stem cells (transient activation of the β-catenin pathway initiates the anagen phase to induce new hair follicle 1,2).

Bulge stem cells self replicate and migrate into the matrix to create new active keratinocytes.



Givaudan

<sup>&</sup>lt;sup>1</sup> Lo Celso et al, 2004

<sup>&</sup>lt;sup>2</sup> Shimizu and Morgan, 2004

### What happens during hair loss?

#### Hair loss is a biological problem.

It happens when the number of hairs in anagen phase is lower than those in the telogen phase.

40% of men will have noticeable hair loss (alopecia) by age 35. It reaches 65% by 60 years of age.

50 to 75% of women suffer noticeable hair loss by age 65.

#### Hair loss has several origins<sup>1</sup>:

- Hormones (androgenic alopecia)
- Stress
- Aging
- Infections

No matter the causes, hair loss happens when the initiation of the new anagen phase (activation of ORS stem cells) is not activated.

<sup>&</sup>lt;sup>1</sup> Chen et al., 2012, J Dermatol Sci




Lossing Languagen phase initiation

## In vitro evaluations

Identifying molecules reactivating the bulge (ORS) stem cells to initiate a new anagen phase.



## DHQG: Dihydroquercetin-glucoside



Origin: Larch tree

MW: 466 g/mol

**Biotechnology optimisation** (glycosylation)


## DHQG: activation of bulge stem cells (in vitro)

#### **PROTOCOL:**

Incubation of human ORS stem cells (hair follicle bulge stem cells) with increasing concentrations of dihydroquercetin-glucoside (DHQG).

## → DHQG enhances the division of the hair follicle ORS stem cells

(Nota:  $50\mu M$  DHQG = 1/3 of the amount tested in the clinical assessment)




\*p<0.01, \*\*\*p<0.001 compared to control, Student's t Test


16


## DHQG: effects on hair follicle stem cells genes (in vitro)

#### **PROTOCOL:**

Incubation of human ORS stem cells (hair follicle bulge stem cells) with different concentrations of dihydroquercetin-glucoside (DHQG). Measure of mRNA expression using qRT-PCR of markers of stem cells' phenotype (K15), anti-apoptosis (BCL2) and differentiation ( $\beta$ -catenin).







Stimulation of the expression of cytokeratin 15

→ DHQG maintains the hair follicle stem cells' phenotype

Stimulation of the expression of BCL2 marker

→ DHQG protects the hair follicle stem cells from apoptosis

Stimulation of the expression of the beta-catenin marker

→ DHQG stimulates the hair follicle stem cells to initiate the anagen phase


## DHQG: stimulation of dermal papilla cells metabolism (in vitro)

#### **PROTOCOL:**

Incubation of human fibroblasts dermal papilla cells (HFDPc) with increasing concentrations of dihydroquercetinglucoside (DHQG).


→ DHQG activates the metabolic activity of HFDPc, for a better nourishment of the hair follicle

(Nota:  $50\mu M$  DHQG = 1/3 of the amount tested in the clinical assessment)



\*p<0.05, \*\*p<0.01, \*\*\*p<0.001 compared to control, Student's t Test

## EGCG2: Epigallocatechin-gallate-glucoside



Origin: Green tea leaves

MW: 604 g/mol

**Biotechnology optimisation** (glycosylation)


## EGCG2: inhibition of interleukin 8 release (in vitro)

#### **PROTOCOL:**

Incubation of human normal keratinocytes with epigallocatechin gallate-glucoside (EGCG2). Measure of interleukin 8 release after induction by IL-1b.

→ EGCG2 inhibits the release of interleukin 8, a cytokine involved in hair loss (Kuwano 2007. Br J Dermatol )

(Nota:  $8\mu M$  EGCG2 = 1/2 of the amount tested in the clinical assessment)



\*p<0.05 compared to control, Student's t Test

### Creation of Redensyl™

#### Based on these research results we combined:

#### **DHQG**

- Activator of stem cell division
- Maintenance of their stem cell properties
- Protection against apoptosis
- Stimulation of dermal fibroblasts metabolism

#### EGCG2


- Highly potent antioxidant
- Inhibitor of interleukin 8 release

#### Zinc, because

- Zn increases incorporation of cystine in hair proteins<sup>1</sup>
- Deficiency in zinc is associated with hair loss

#### Glycine, one of the top 10 amino acid in hair

- The main structural proteins in the hair fiber are the hair keratins and the hair keratin-associated proteins, KAPs
- The KAPs possess either high cysteine or high glycine-tyrosine content <sup>2</sup>




<sup>&</sup>lt;sup>1</sup> Hsu et al., 1971, J. Nutr. 101.

<sup>&</sup>lt;sup>2</sup> Rogers et al., 2002, JBC Papers in Press.

# Redensyl<sup>TM</sup>: Activation of $\beta$ -Catenin (in vitro)

#### **PROTOCOL:**

Western blot analysis run on human androgenic alopecic ORSc (3 donors) treated with Redensyl<sup>TM</sup>. Measurement of  $\beta$ -Catenin activation.




 $\rightarrow$  Redensyl<sup>TM</sup> activates  $\beta$ -Catenin in androgenic alopecia ORSc which confirms the very good results observed during the q-RT PCR with DHQG.

## EGCG2: inhibition of interleukin 8 release (in vitro)

#### **PROTOCOL:**

Apoptosis Annexin V assay run on human androgenic alopecic ORSc (3 donors) treated with Redensyl™. Measurement of living cells situation proportions.

→ Redensyl<sup>™</sup> protects androgenic alopecia ORSc from apoptosis which confirms the very good results observed during the q-RT PCR with DHQG.




## Ex vivo evaluations



### Hair follicle growth test (Philpott test)

#### **PROTOCOL:**

24 hair follicles from men suffering from alopecia were maintained alive with either 1% of Minoxidil or 1% of Redensyl™ during 10 days. Hair growth was measured at D7 and D10.



\*\*p<0.1, \*\*\*p<0.001 compared to untreated, Student's t Test

- → Redensyl<sup>™</sup> increases hair growth by +214% compared to untreated
- → Redensyl<sup>™</sup> acts almost 2x more than Minoxidil, the benchmark reference.

## Clinical evaluation




#### Protocol of clinical trial

#### **VOLUNTEERS**

- 26 men aged 18 to 70 years old
- Brown to dark hair
- Qualified for a grade 3 to 4 alopecia (Norwood scale)
- With minimum 150 hair/cm2 and 40 telogen hairs/cm2

#### **PROTOCOL**

- Double blind clinical trial versus a placebo
- Applying the formula once a day
- 50% of volunteers received the placebo
- 50% received the formula with 3% Redensyl™
- Clinical study was performed under the control of a dermatologist.
- Period of the test: autumn



Clinical formula: AQUA, ALCOHOL DENAT., BUTYLENE GLYCOL, GLYCERIN, XANTHAN GUM, DISODIUM EDTA, CITRIC ACID, (+/-) REDENSYL™ 3%

27


## Evaluated parameters

#### Clinical measures at D0, D30 and D84

- Macro pictures on scalp
- Density of hair in anagen phase
- Density of hair in telogen phase
- Ratio anagen/telogen
- Pictures of the head
- Self assessment questionnaire at D84

#### Nota:

- Shaving of a 1.5 cm<sup>2</sup> area
- Analysis on 0,7 cm<sup>2</sup>




## Counting of anagen hair (=growing)

#### **PROTOCOL:**

Analysis of the volunteers' scalp of the number of hair in anagen phase.

- → Slight non significant placebo effect up to D84 (activation of microcirculation)
- → Redensyl<sup>™</sup> stimulates up to +9% the number of hair in anagen phase.




\*\*p<0.01, compared to untreated, Student's t Test

## Counting of telogen hair (=falling)

#### **PROTOCOL:**

Analysis of the volunteers' scalp of the number of hair in telogen phase.

- → Slight non significant placebo effect up to D84 (activation of microcirculation)
- → Redensyl<sup>™</sup> reduces down to -17% the number of hair in telogen phase.




\*\*p<0.01, compared to untreated, Student's t Test

## Follow up of the anagen/telogen ratio

#### **PROTOCOL:**

Analysis of the volunteers' scalp of the number of the ratio of anagen versus telogen hair.

→ After 3 months, Redensyl<sup>™</sup> improves the ratio of anagen/telogen by +29%, reaching 2.37 from the initial 1.83




### Pictures of volunteers

Increased density 52 years old

Reduction of the vortex 38 years old

Reduction of the bald area diameter 42 years old




### Pictures of volunteers

Increased density 46 years old


Reduction of the vortex 36 years old

Increased density 29 years old



## Details – before/after


Criteria	#3
Age	52 years old
% of new anagen hair	+ 10.8%
% of density of hair increase	+ 17%
Number of new hairs / cm <sup>2</sup>	+ 47 hairs/ cm²
Total number of new hairs on the scalp (600 cm <sup>2</sup> )	+ 28,200 hairs
Number of new hair per month on the scalp	+ 9,400 hairs



#### → Visible redensification of the scalp

## Details – before/after


Criteria	#6
Age	42 years old
% of new anagen hair	+ 19.2%
% of density of hair increase	+ 17%
Number of new hairs / cm <sup>2</sup>	+ 43 hairs / cm²
Total number of new hairs on the scalp (600 cm²)	+ 25,800 hairs
Number of new hair per month on the scalp	+ 8,600 hairs



→ Hair loss stopped, a visible increase of hair density

## Details – before/after

Volunteer	#26
Age	29 years old
% of new anagen hair	+ 9.2%
% of density of hair increase	+ 17%
Number of new hairs / cm <sup>2</sup>	+ 29 hairs / cm²
Total number of new hairs on the scalp (600 cm²)	+ 17,400 hairs
Number of new hairs per month on the scalp	+ 5,800 hairs




→ Hair looks thicker with a visible improvement of the density

#### Self assessment

#### A self-evaluation run by the volunteers after 84 days.


Testers claim to see reduced hair loss, improved capillary density, stronger and thicker hair after three months of treatment.




#### Self assessment

#### A self-evaluation run by the volunteers after 84 days.

71% of the testers are satisfied by the product, and 71% of them would like to buy the product.





## Summary of the clinical assessment


Within 84 days on grade 3 to 4 alopecic volunteers:

85% of volunteers showed clinical improvements:


- √ +9% of anagen hair
- ✓ **-17%** of telogen hair
- √ +29% in the anagen/telogen ratio
- ✓ An average +8% increase of hair density, corresponding to,
  - √ +10,000 new hairs on a total 600 cm²
    scalp surface
  - ✓ Up to +28,200 new hairs



# Summary




## Redensyl<sup>TM</sup> - the Hair Growth Galvanizer



## Targeting existing hair follicle stem cells

- 1. A reactivation of the bulge stem cells
- 2. A metabolic boost of dermal papilla cells
- 3. A shut down of inflammatory reactions
- 4. Excellent results on grade 3 to 4 alopecic volunteers:
  - Hair are denser
  - Hair look thicker
  - Increase in hair growth
  - Decrease in hair loss
  - A better ratio anagen/telogen
  - Visible results in 84 days



### Comparison with esthetic surgery

#### Hair transplantation surgery:

- A hair transplantation surgery enables to make an average of 2016 grafts <sup>1</sup>
- Grade 3 to grade 4 alopecic patients need between 1600 to 2200 hair grafts<sup>2</sup>
- Each graft contains 4 hair <sup>2</sup>, so each transplantation gives 6400 to 8800 new hairs
- 65% of the patients undergo a single hair transplantation <sup>1</sup>
- Up to 3 hair grafts sessions can be needed to get the appropriate hair density <sup>1</sup>
- → Redensyl<sup>™</sup> gives better results than one hair transplantation surgery (+10,000 new hairs in average, up to +28,200)



<sup>&</sup>lt;sup>1</sup> International Society of Hair Restoration Surgery: 2013 Practice Census Results

<sup>&</sup>lt;sup>2</sup> Bernstein Medical center <u>www.bernsteinmedical.com/hair-transplant/follicular-unit-transplantation/graft-numbers/</u>

## **Applications**

### **MEN**

- Anti hair loss lotion and shampoo
- Hair growth spray
- Anti aging global hair serum
- Shampoo for thin hair
- Preventive hair care shampoo

### **WOMEN**

- Mask, or leave-on hair care products
- Preventive hair care shampoo
- Post trauma hair treatment
- Anti aging global hair serum
- Eyelash growth mascara
- Eyelash growth primer
- Eyebrows redensifier



# Technical information $Redensyl^{TM}$

INCI

Glycerin (And) Water (And) Sodium Metabisulfite (And) Glycine (And) Larix Europaea Wood Extract (And) Zinc Chloride (And) Camellia Sinensis Leaf Extract

**Origin** White and Green technologies

**Preservation** Preservative free

Appearance Clear yellow solution

Solubility Water soluble

Dosage 1% to 3%

**Processing** 

Can be added at the end of the formulation process under stirring below 50°C. Can be heated for a short term with the oil phase of formulation

Compliance







